Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 1.00 |
| ▸ | HTR2B | P41595 | 13/20 | 1.00 |
| ▸ | HTR2C | P28335 | 13/20 | 1.00 |
| ▸ | HTR7 | P34969 | 12/20 | 1.00 |
| ▸ | HTR1A | P08908 | 11/20 | 1.00 |
| ▸ | DRD1 | P21728 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TDP2 | O95551 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CASP3 | P42574 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 2/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PTPRCAP | Q14761 | 1/20 | 1.00 |
| ▸ | APAF1 | O14727 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glaucine SCHEMBL29735463 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| Glaucine SCHEMBL30213021 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| Glaucine SCHEMBL146441 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| Glaucine SCHEMBL11158386 | 0.99 | KDM4E (1.00) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| Glaucine SCHEMBL11249152 | 0.99 | KDM4E (1.00) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| Glaucine SCHEMBL11166124 | 0.99 | HTR2A (0.97) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| Glaucine SCHEMBL4312401 | 0.94 | HTR2A (0.88) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| Glaucine SCHEMBL7389697 | 0.93 | HTR2B (0.86) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| SCHEMBL4854015 | 0.92 | HTR7 (1.00) | HTR2AHTR2BHTR2CHTR7HTR1A | |
| SCHEMBL30475142 | 0.92 | HTR7 (1.00) | HTR2AHTR2BHTR2CHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354926-B2 | Molecules derived from noraporphine | SEDERMA SAS (FR) | 2008-04-08 | — | — | US | claimed |
| EP-1534682-B1 | NOVEL MOLECULES DERIVED FROM NORAPORPHINE | SEDERMA S A S (FR) | 2006-12-27 | — | — | EP | claimed |
| US-20060110413-A1 | Novel Molecules dervied from noraporphine | SEDERMA (FR) | 2006-05-25 | — | — | US | claimed |
| EP-1534682-A1 | NOVEL MOLECULES DERIVED FROM NORAPORPHINE | Sederma S.A.S. (FR) | 2005-06-01 | — | — | EP | claimed |
| WO-2004024695-A1 | NOVEL MOLECULES DERIVED FROM NORAPORPHINE | SEDERMA S.A.S. (FR) | 2004-03-25 | — | — | WO | claimed |
| EP-4210675-A1 | TISSUE-DERIVED MATRIKINE COMPOSITIONS AND METHODS THEREFOR | Xylyx Bio, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4084789-A1 | PPAR AGONIST COMPLEX AND METHODS OF USE | Rodan & Fields LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2021138031-A1 | PPAR AGONIST COMPLEX AND METHODS OF USE | RODAN & FIELDS, LLC (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| US-20170136029-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | IRM LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| EP-1949887-A2 | Cosmetic formulas for skin smoothing and tautening | Henkel AG & Co. KGaA (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-7354926-B2 | Molecules derived from noraporphine | SEDERMA SAS (FR) | 2008-04-08 | — | — | US | disclosed |
| EP-1813310-A2 | Cosmetic stick based on an oil in water dispersion/emulsion | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1534682-B1 | NOVEL MOLECULES DERIVED FROM NORAPORPHINE | SEDERMA S A S (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060110413-A1 | Novel Molecules dervied from noraporphine | SEDERMA (FR) | 2006-05-25 | — | — | US | disclosed |
| EP-1534682-A1 | NOVEL MOLECULES DERIVED FROM NORAPORPHINE | Sederma S.A.S. (FR) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004024695-A1 | NOVEL MOLECULES DERIVED FROM NORAPORPHINE | SEDERMA S.A.S. (FR) | 2004-03-25 | — | — | WO | disclosed |
| US-4309542-A | WITH A TRIMETHYLPHENYLAMMONIUM BASE | WARNER-LAMBERT COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060110413-A1 | Novel Molecules dervied from noraporphine | DPM1, NPM1, TYR | HTR2A 2427/4885HTR2B 3104/4885HTR2C 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.